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Background: Low bone mineral density (BMD) is prevalent in adults with cystic fibrosis and might be related to calcium and vitamin D
malabsorption from the gastrointestinal tract. The aim of this study was to investigate the effect of calcium and vitamin D supplementation on
BMD and bone metabolism in these subjects.
Methods: Patients were invited to participate if they had a BMD Z score of 1 or less in the lumbar spine, proximal femur or distal forearm.
Patients were randomised to receive calcium 1 g+vitamin D 800 IU or placebo daily, in addition to their regular vitamin D supplements (900
IU/day). BMD and bone biochemical markers were measured before and after 1 year of treatment.
Results: After 12 months, the treatment group (n=15) showed a reduced rate of bone loss compared with the control group (n=15) in the
lumbar spine (mean difference 1.9% [CI 0.9% to 4.6%]), total hip (mean difference 0.7% [CI 2.2% to 3.5%]) and distal forearm (mean
difference 1.7% [CI 2.2% to 5.5%]), but these changes did not reach statistical significance. There was also a trend towards a reduction in
bone turnover in the treatment group.
Conclusions: Calcium and vitamin D supplementation reduced the rate of bone turnover and bone loss in adult patients with cystic fibrosis,
but these changes did not reach statistical significance. These data suggest that a longer term trial of this simple intervention would be
justified.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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Low bone mineral density (BMD) is prevalent in adults
with cystic fibrosis [1–5]. In a cross-sectional study of 151
patients, 34% had a BMD Z score of 2 or less at the
lumbar spine, proximal femur or distal forearm [2]. This
reduction in BMD probably explains the increased rate of
fracture observed in CF adults compared to the general1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.08.002
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bone mass decreases in adolescents and young adults with
CF [6], and as patients live longer, the fracture rate is likely
to increase as a consequence of normal age-related bone
loss. The aetiology of low BMD in the cystic fibrosis
population is multifactorial [7], with low bone mass being
related to the severity of cystic fibrosis disease [2–5] and
levels of systemic inflammation [8], general malnutrition
[2–5], reduced levels of physical activity [2–5], oral
corticosteroid use [1,3,4], diabetes [4], hypogonadism [4],
vitamin K deficiency [9], calcium malabsorption [10] and
vitamin D insufficiency [2,11]. Bone histomorphometry
studies suggest that the predominant abnormality is reduced3 (2004) 233–236ed by Elsevier B.V. All rights reserved.
C.S. Haworth et al. / Journal of Cystic Fibrosis 3 (2004) 233–236234bone formation with some patients showing evidence of
increased resorption [12,13].
While bisphosphonate therapy is indicated in selected
patients with cystic fibrosis at high risk of developing
fragility fractures, there is a need to evaluate a more
universally applicable means of increasing and preserving
bone mass in the cystic fibrosis population. For this reason,
we evaluated the effect of calcium and vitamin D
supplementation on bone mineral density and bone metab-
olism in adult patients with cystic fibrosis.Table 1
Percentage change in bone mineral density after 12 months treatment
Calcichew
group
n=15 (%)
Control
group
n=15 (%)
Mean (95% CI)
difference in
changes between
groups (%)
p
value
Lumbar spine 0.0 1.9 1.9(0.9 to 4.6) NS
Total hip 0.4 1.1 0.7(2.2 to 3.5) NS
Distal forearm 0.8 2.5 1.7(2.2 to 5.5) NS2. Methods
In 1999, after 2 years of follow-up in a longitudinal
BMD study, patients with cystic fibrosis aged 18 years old
or over who had a BMD Z score of 1 or less in the lumbar
spine, total hip or distal forearm were invited to participate
in this treatment trial. Thirty-one (56%) of the 55 eligible
patients agreed to participate. All patients were attending the
Manchester Adult Cystic Fibrosis Unit, and the diagnosis of
cystic fibrosis was confirmed by gene analysis. The South
Manchester Research Ethics Committee approved the study,
and each patient provided written informed consent.
Patients were randomised to receive either calcium 1 g +
vitamin D 800 IU (Calcichew D3 Forte, one tablet twice
daily, Shire Pharmaceuticals, Andover, Hants, UK) or
placebo one tablet twice daily for 1 year. All patients were
pancreatic insufficient and were advised to continue to take
their long-term vitamin D supplements (900 IU daily).
2.1. Bone mineral density measurements
BMD was measured in the lumbar spine (L1-4) and
proximal femur (total hip) by dual energy X-ray absorpti-
ometry (QDR 4500 Acclaim densitometer, Hologic, Bed-
ford, MA, USA) and in the distal forearm (trabecular BMD)
by peripheral quantitative tomography (XCT 2000 densi-
tometer, STRATEC Medizintechnik, Pforzheim, Germany)
at the beginning and end of the study. The short-term
departmental precision for each bone densitometry techni-
que was derived from repeated measurements in 10 subjects.
Expressed as a coefficient of variation, the short-term
precision was 1.1% in the lumbar spine, 1.3% in the total
hip and 0.78% in the distal forearm. The baseline BMD
results were expressed as Z scores, and the reference data
were provided by the densitometer manufacturers. The
percentage change in BMD over the treatment period was
calculated from the absolute BMD values measured at the
beginning and end of the study.
2.2. Biochemical measurements
Morning blood and urine samples were taken from
patients on recruitment to the study and after 12 months
treatment, at a time when their lung disease was stable.Serum concentrations of 25-hydroxyvitamin D, parathyroid
hormone, corrected calcium, osteocalcin, bone specific
alkaline phosphatase and urinary deoxypyridinoline cross-
links were analysed, as described previously [2]. The
interassay and intra-assay coefficients of variation for the
25-hydroxyvitamin D measurements were 8.8% and 7.8%,
respectively.
2.3. Clinical Assessment
The best recorded forced expiratory volume in one
second (FEV1), weight and height in the 4 months prior to
the recruitment visit were used to calculate the percentage
predicted FEV1 [14] and body mass index (BMI). The
prescription of oral corticosteroid therapy was recorded
throughout the study. Daily oral calcium intake was assessed
on recruitment to the study using a validated questionnaire
[15]. At the end of the study, patients were interviewed to
record adverse events and adherence to treatment.
2.4. Statistical analysis
Data were analysed using SPSS version 9.0 (SPSS,
Chicago, IL). The continuous variables were summarised
using the mean (S.D.). Differences between the treatment
and placebo groups were identified using the unpaired
Student’s t test and summarised using the mean (95%
confidence levels [CI]).3. Results
3.1. Patient characteristics
Thirty-one adults with cystic fibrosis were recruited to
the trial. None of the patients had received a transplant or
received bone-sparing agents in the past, except for standard
vitamin D supplements. Sixteen patients (seven males) were
randomised to the Calcichew D3 Forte group (treatment
group), and 15 patients (eight males) were randomised to the
placebo group (control group). One patient withdrew from
the treatment group due to pregnancy. Eight patients in each
group received oral corticosteroid therapy during the trial
period.
On recruitment to the study the mean (S.D.) age,
percentage predicted FEV1, BMI and dietary calcium intake
Table 2
Absolute change in bone biochemistry after 12 months treatment
Calcichew
group
n=15
Control
group
n=15
Mean (95% CI)
difference in changes
between groups
p
value
Osteocalcin
(ng/ml)
0.8 0.1 0.7(3.8 to 2.3) NS
BSAP (U/l) 0.5 1.3 1.8(6.6 to 3.0) NS
Crosslinks
(nM/mM)
1.0 0.8 1.8(3.8 to 0.2) NS
Corrected
Calcium
(mmol/l)
0.03 0.02 0.01(0.06 to 0.09) NS
25-OHD
(ng/ml)
0.5 4.1 3.6(9.1 to 1.8) NS
PTH (pg/ml) 6.0 5.3 0.7(8.7 to 10.1) NS
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the control group were 29.4 (7.8) vs. 25.9 (8.0) years (NS);
66.1 (28.4)% vs. 60.9 (13.9)% predicted (NS); 23.0 (2.1) vs.
21.1 (1.7) kg/m2 ( p=0.01); and 837 (512) vs. 1077 (506)
mg/day (NS), respectively.
3.2. Bone mineral density and bone biochemistry
The mean (S.D.) baseline BMD Z scores in the
treatment and placebo groups were 1.4 (0.7) vs. 1.3
(0.8) in the lumbar spine (NS); 1.0 (0.7) vs. 0.8 (0.9)
in the total hip (NS); and 0.7 (1.1) vs. 1.0 (1.0) in the
distal forearm (NS), respectively. The mean (S.D.) base-
line 25hydroxyvitamin D, PTH and serum corrected
calcium concentrations in the treatment group compared
to the control group were 24.4 (10.2) vs. 21.6 (10.8) ng/
ml [NS]; 27.2 (7.4) vs. 28.1 (12.2) pg/ml [NS]; and 2.25
(0.07) vs. 2.29 (0.07) mmol/l (NS), respectively. There
were no significant differences in the baseline markers of
bone formation and bone resorption between the treatment
and control groups.
The mean differences in the changes in BMD and bone
biochemical markers between the two groups after 1 year of
treatment are recorded in Tables 1 and 2.
3.3. Adherence and adverse events
The mean (S.D.) reported adherence to treatment was
3.1 (2.5) days/week in the treatment group compared to
3.7 (2.6) days/week in the placebo group, (NS). The
patients did not report any significant adverse events with
drug or placebo, and there were no documented episodes
of hypercalcaemia.4. Discussion
Oral calcium and vitamin D supplementation reduced
the rate of bone turnover and bone loss in adult patients
with cystic fibrosis, but these changes did not reachstatistical significance. This probably reflects the small
number of patients studied and the relatively short
intervention period. This is the first published trial
reporting the effect of calcium and vitamin D supplemen-
tation on bone density in patients with cystic fibrosis, and
we believe that these findings support a possible ther-
apeutic benefit in axial and peripheral sites of the skeleton.
The use of peripheral quantitative computed tomography, a
volumetric measure of bone density, confirms that the
changes in bone density were not significantly influenced
by body size or growth.
There was no significant difference in the change in 25-
hydroxyvitamin D concentration between the treatment and
placebo groups after 1 year. This was an unexpected finding
as the treatment group received an additional 800 IU
vitamin/day compared to the placebo group. Lark et al.
[11] evaluated vitamin D malabsorption in patients with
cystic fibrosis by measuring the absorption of vitamin D2 in
10 pancreatic-insufficient patients and 10 healthy controls.
The CF patients absorbed less than half the amount
absorbed by controls, and vitamin D absorption was
negligible in two patients. Our data are further supported
by the findings of Boyle et al. [16] who recorded negligible
increases in 25-hydroxyvitamin D levels following treat-
ment with ergocalciferol 50,000 IU weekly or twice weekly
for up to 4 months. Thus, increased oral vitamin D
supplementation fails to replenish vitamin D stores in many
patients with cystic fibrosis and other strategies such as
increased solar exposure may be required.
However, the relative importance of 25-hydroxyvitamin
D insufficiency in the pathogenesis of CF related low BMD
has been questioned by the results of a recent study from
Australia [17]. Despite vitamin D sufficiency, bone resorp-
tion markers were increased and lumbar spine BMD
reduced in adolescent and adult CF patients compared to
age- and sex-matched controls. Interestingly, 1,25-dihy-
droxyvitamin D levels were lower in patients than controls,
consistent with decreased hydroxylation of vitamin D within
the kidney or increased consumption. This might explain the
promising results of Brown et al. [18] who showed that
calcitriol (1,25-dihydroxyvitamin D) increases the fractional
absorption of calcium and decreases bone resorption marker
concentrations in adults with cystic fibrosis.
Aris et al. [10] demonstrated that the fractional absorp-
tion of 45Ca from the gastrointestinal tract was significantly
impaired in pancreatic insufficient adults with cystic
fibrosis. The addition of pancreatic enzyme supplements
did not increase the fractional absorption of calcium, and the
authors suggested that the intrinsic absorptive capacity of
the intestine might be impaired due to the chronic low grade
inflammation in the mucosa of the gastrointestinal tract [10].
In view of the relatively low dietary calcium intake recorded
in our patients at the start of the study, this might explain
why calcium and vitamin D supplementation reduced the
rate of bone loss in the absence of any demonstrable effect
on 25-hydroxyvitamin D levels.
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CF adults in two randomised studies. Intravenous pamidr-
onate caused rapid increases in axial BMD [19] but was
associated with severe bone pain in non-corticosteroid
treated patients [20,21]. More recently, daily oral alendro-
nate was shown to increase bone mass compared to placebo
in the lumbar spine (+4.9 (3.0)% vs. 1.8 (4.0)%, p V
0.001) and femur (+2.8 (3.2)% vs. 0.7 (4.7)%, p= 0.003)
[22]. While bisphosphonates are indicated in CF patients
actively losing bone despite optimisation of their clinical
status, calcium and vitamin D supplementation (although
less potent) may be beneficial to a wider proportion of the
CF population, such as those with insufficient dietary
calcium intake or prior to the pubertal growth spurt.
Calcium and vitamin D supplementation is also probably
the safest bone sparing treatment for women wishing to
become pregnant because of the potential teratogenic effects
and long half-life of bisphosphonates.
The results of this study must be interpreted with care, as
it is underpowered in terms of the number of participants
and the length of the intervention. However, it is a pilot
study and provides novel data from which larger studies
could be powered. Calcium and vitamin D supplementation
might have a more marked effect on bone metabolism if
implemented prior to the pubertal growth spurt, and so
larger studies should include this population.
In conclusion, calcium and vitamin D supplementation
reduced the rate of bone turnover and bone loss in adult
patients with cystic fibrosis, but these changes did not reach
statistical significance. These data suggest that bone loss
might be reduced by longer term treatment with this simple
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